LTR Pharma Ltd (LTP) - Total Liabilities
Based on the latest financial reports, LTR Pharma Ltd (LTP) has total liabilities worth AU$457.81K AUD (≈ $323.93K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LTR Pharma Ltd - Total Liabilities Trend (2021–2025)
This chart illustrates how LTR Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. See LTP net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
LTR Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of LTR Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DOMESCO Medical Import Export JSC
VN:DMC
|
Vietnam | ₫205.43 Billion |
|
Great Elm Capital Corp
NASDAQ:GECC
|
USA | $175.29 Million |
|
GIIB Holdings Bhd
KLSE:7192
|
Malaysia | RM67.48 Million |
|
Sanko Pazarlama Ithalat Ihracat AS
IS:SANKO
|
Turkey | TL1.63 Billion |
|
Airtasker Ltd
AU:ART
|
Australia | AU$80.74 Million |
|
Renergen Ltd.
JSE:REN
|
South Africa | ZAC1.70 Billion |
|
Formosa Electronic Industries
TWO:8171
|
Taiwan | NT$1.06 Billion |
|
WeConnect
PA:ALWEC
|
France | €246.84 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down LTR Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LTP stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 57.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LTR Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LTR Pharma Ltd (2021–2025)
The table below shows the annual total liabilities of LTR Pharma Ltd from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$700.57K ≈ $495.70K |
+63.48% |
| 2024-06-30 | AU$428.54K ≈ $303.22K |
+1915.71% |
| 2023-06-30 | AU$21.26K ≈ $15.04K |
-95.53% |
| 2022-06-30 | AU$475.91K ≈ $336.74K |
+2.68% |
| 2021-06-30 | AU$463.50K ≈ $327.96K |
-- |
About LTR Pharma Ltd
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more